Home

Erin Lavelle

CIK 1737613 · COO & CFO · last filed 2026-06-11

Erin Lavelle is a COO & CFO who has filed 12 SEC Form 4 insider transactions across 5 companies since 2018. The most recent filing, for JBIO, was dated Jun 11, 2026. Across all open-market trades the lifetime net is −$19.6K, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

5

Total Filings

12

Lifetime Open-Market Net

-$19.6K

Filer Profile

Reported Address
C/O JADE BIOSCIENCES, INC.
221 CRESCENT STREET, BLDG 23, SUITE 105
WALTHAM, MA 02453
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
JBIO Director — $14.58 — $0 2 2026-06-11
AVLN Director — $28.12 — $0 1 2026-05-01
Neurogene Inc. (NLTX) Delisted Director — $13.96 — $0 2 2023-06-09
Climb Bio, Inc. (ELYM) Delisted COO & CFO — $5.11 — $0 2 2022-11-02
ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted Chief Operating Officer 4,408 — — -$19.6K 3 2019-04-25

Recent Filings

12 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-11 JBIO Grant (A) — $0 EDGAR
2026-05-01 AVLN Grant (A) — $0 EDGAR
2025-05-01 JBIO Grant (A) — $0 EDGAR
2024-02-06 NGNE Notice (144) −2,500 -$76.1K EDGAR
2023-06-09 Neurogene Inc. (NLTX) Delisted Grant (A) — $0 EDGAR
2022-11-02 Climb Bio, Inc. (ELYM) Delisted Grant (A) — $0 EDGAR
2022-05-16 Neurogene Inc. (NLTX) Delisted Grant (A) — $0 EDGAR
2022-01-31 Climb Bio, Inc. (ELYM) Delisted Grant (A) — $0 EDGAR
2019-10-24 — Mixed −4,408 -$289.7K
2019-04-25 ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted Mixed +4,408 -$19.6K EDGAR
Showing 1–10 of 12
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.